Athira Pharma, Inc.

Equities

ATHA

US04746L1044

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 11:41:49 03/06/2024 pm IST			5-day change	1st Jan Change
2.59 ^USD	-1.15%		+1.70%	+7.14%

15/05	Athira Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
15/04	Athira Pharma, Inc. Appoints Javier San Martin, M.D., as Chief Medical Officer	CI

Athira Pharma, Inc. Announces Chief Executive Officer Changes

October 22, 2021 at 01:35 am IST

Athira Pharma, Inc. announced the appointment of Mark Litton, Ph.D., M.B.A. as Chief Executive Officer of the company. Dr. Litton succeeds Dr. Leen Kawas, who has resigned from her position as the company?s Chief Executive Officer.

Latest news about Athira Pharma, Inc.

Athira Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
Athira Pharma, Inc. Appoints Javier San Martin, M.D., as Chief Medical Officer	15/04	CI
Athira Pharma, Inc. Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease	11/04	CI
Athira Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	23/02	CI
Athira Pharma, Inc. Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis	09/02	CI
Athira Pharma, Inc. Provides 2024 Clinical Pipeline Outlook	08/01	CI
Athira Pharma, Inc. Announces Hans Moebius Retires as Chief Medical Officer	08/01	CI
Athira Pharma, Inc. Completes Enrollment of Phase 2/3 Lift-AD Clinical Trial of Fosgonimeton in Mild-To-Moderate Alzheimer's Disease	03/01	CI
Athira Pharma, Inc. Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid-B-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer's Disease	15/11	CI
Athira Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Athira Says Preclinical Results Back Therapeutic Potential of ATH-1105 in ALS; Shares Rise After Hours	06/23/06	MT
JMP Securities Adjusts Athira Pharma Price Target to $19 From $20, Maintains Market Outperform Rating	11/23/11	MT
Athira Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Athira Pharma, Inc. Appoints Andrew Gengos as Chief Business Officer	11/23/11	CI
Athira Pharma, Inc. Appoints Andrew Gengos as Chief Financial Officer	11/23/11	CI
Athira Pharma, Inc. Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimerâ€™s Disease	17/23/17	CI
Athira Pharma, Inc.(NasdaqGS:ATHA) dropped from Russell Small Cap Comp Value Index	23/23/23	CI
Athira Pharma, Inc.(NasdaqGS:ATHA) dropped from Russell 3000 Index	23/23/23	CI
Athira Pharma, Inc.(NasdaqGS:ATHA) dropped from Russell Small Cap Completeness Index	23/23/23	CI
Athira Pharma, Inc.(NasdaqGS:ATHA) dropped from Russell 2500 Index	23/23/23	CI
Athira Pharma, Inc.(NasdaqGS:ATHA) dropped from Russell 2000 Index	23/23/23	CI
Athira Pharma, Inc.(NasdaqGS:ATHA) dropped from Russell 3000E Value Index	23/23/23	CI
Athira Pharma, Inc.(NasdaqGS:ATHA) dropped from Russell 3000E Index	23/23/23	CI
Athira Pharma, Inc.(NasdaqGS:ATHA) dropped from Russell 3000 Value Index	23/23/23	CI
Athira Pharma, Inc.(NasdaqGS:ATHA) dropped from Russell 2000 Value Index	23/23/23	CI

Chart Athira Pharma, Inc.

Duration

Period

More charts

Company Profile

Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company. It focuses on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline consists of both blood brain barrier permeable and peripherally restricted drug candidates for the central nervous system (CNS), peripheral nervous system, and other indications. Its lead candidate, fosgonimeton (ATH-1017), is a subcutaneously administered, small molecule positive modulator of the hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) system for CNS disorders. It is also evaluating other drug candidates for the potential treatment of neuropathic pain, amyotrophic lateral sclerosis, Parkinson's disease, and other neurodegenerative diseases. Its ATH-1020 has completed a Phase I single ascending dose evaluation in healthy volunteers. Its ATH-1105 is a small molecule compound designed to be an orally available, once-daily treatment to enhance the HGF/MET system.

Sector

Biotechnology & Medical Research

Calendar

06/06/2024 - Jefferies Global Healthcare Conference

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.62 USD

Average target price

7.275 USD

Spread / Average Target

+177.67%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ATHIRA PHARMA, INC.	+7.14%	100M
MODERNA, INC.	+46.83%	54.63B
IQVIA HOLDINGS INC.	-6.51%	39.92B
LONZA GROUP AG	+37.07%	38.82B
ICON PUBLIC LIMITED COMPANY	+13.55%	26.86B
CELLTRION, INC.	-11.17%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-21.35%	18.78B
UNITED THERAPEUTICS CORPORATION	+24.99%	12.21B
BIO-TECHNE CORPORATION	+1.02%	12.16B
MEDPACE HOLDINGS, INC.	+25.97%	11.94B

Other Biotechnology & Medical Research